Dysbiosis has been described in systemic autoimmune diseases (SADs), including systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), and primary anti-phosholipid syndrome (PAPS), however the biological implications of these associations are often elusive. Stool and plasma samples from 114 subjects, including in SLE (n = 27), SjS (n = 23), PAPs (n = 11) and undifferentiated connective tissue (UCTD, n = 26) patients, and geographically-matched healthy controls (HCs, n = 27), were collected for microbiome (16s rRNA gene sequencing) and metabolome (high-performance liquid chromatography coupled to mass spectrometry) analysis to identify shared characteristics across diseases. Out of 130 identified microbial genera, a subset of 29 bacteria was able to differentiate study groups (area under receiver operating characteristics (AUROC) = 0.730 ± 0.025). A fair classification was obtained with a subset of 41 metabolic peaks out of 254 (AUROC = 0.748 ± 0.021). In both models, HCs were well separated from SADs, while UCTD largely overlapped with the other diseases. In all of the SADs pro-tolerogenic bacteria were reduced, while pathobiont genera were increased. Metabolic alterations included two clusters comprised of: (a) members of the acylcarnitine family, positively correlating with a Prevotella-enriched cluster and negatively correlating with a butyrate-producing bacteria-enriched cluster; and (b) phospholipids, negatively correlating with butyrate-producing bacteria. These findings demonstrate a strong interaction between intestinal microbiota and metabolic function in patients with SADs.

Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases / C. Bellocchi, Á. Fernández-Ochoa, G. Montanelli, B. Vigone, A. Santaniello, R. Quirantes-Piné, I. Borrás-Linares, M. Gerosa, C. Artusi, R. Gualtierotti, A. Segura-Carrettero, M.E. Alarcón-Riquelme, L. Beretta. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:9(2019 Aug 23), pp. 1291.1-1291.15.

Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases

C. Bellocchi;G. Montanelli;B. Vigone;A. Santaniello;M. Gerosa;C. Artusi;R. Gualtierotti;
2019

Abstract

Dysbiosis has been described in systemic autoimmune diseases (SADs), including systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), and primary anti-phosholipid syndrome (PAPS), however the biological implications of these associations are often elusive. Stool and plasma samples from 114 subjects, including in SLE (n = 27), SjS (n = 23), PAPs (n = 11) and undifferentiated connective tissue (UCTD, n = 26) patients, and geographically-matched healthy controls (HCs, n = 27), were collected for microbiome (16s rRNA gene sequencing) and metabolome (high-performance liquid chromatography coupled to mass spectrometry) analysis to identify shared characteristics across diseases. Out of 130 identified microbial genera, a subset of 29 bacteria was able to differentiate study groups (area under receiver operating characteristics (AUROC) = 0.730 ± 0.025). A fair classification was obtained with a subset of 41 metabolic peaks out of 254 (AUROC = 0.748 ± 0.021). In both models, HCs were well separated from SADs, while UCTD largely overlapped with the other diseases. In all of the SADs pro-tolerogenic bacteria were reduced, while pathobiont genera were increased. Metabolic alterations included two clusters comprised of: (a) members of the acylcarnitine family, positively correlating with a Prevotella-enriched cluster and negatively correlating with a butyrate-producing bacteria-enriched cluster; and (b) phospholipids, negatively correlating with butyrate-producing bacteria. These findings demonstrate a strong interaction between intestinal microbiota and metabolic function in patients with SADs.
Sjögren’s syndrome; metabolomics; microbiomic; primary anti-phosholipid syndrome; systemic autoimmune diseases; systemic lupus erythematosus; undifferentiated connective tissue diseases
Settore MED/16 - Reumatologia
   Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases
   PRECISESADS
   EUROPEAN COMMISSION
   115565
23-ago-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
jcm-08-01291-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.22 MB
Formato Adobe PDF
1.22 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/673276
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 37
social impact